The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Whisky from the northern area is milder because it is made using spring water for a "lighter flavoured, mossy (rather than peaty), with some seaweed, some nuts" characteristic. The national tourist board website says that the single malts from Islay vary by distillery, from "robust and smoky" to "lighter and sweeter". The Lowlands: According to Visit Scotland, the website of the national tourist board, this district covers "much of the Central Belt and the South of Scotland including Edinburgh & The Lothians, Glasgow & The Clyde Valley, the Kingdom of Fife, Ayrshire, Dumfries & Galloway and the Scottish Borders". There were 18 Lowlands distilleries in the region as of 2019, according to the website of the national tourist board, including some that opened quite recently. These include well-known companies such as Annandale, Auchentoshan, Bladnoch, Glenkinchie, and Ailsa Bay in the site of the Girvan distillery as well as Daftmill, Eden Mill, Kingsbarns and Rosebank. Region characteristics: soft and smooth, consisting of a floral nose with a sweet finish. Single malts from this area tend to be "lighter, sweet and [with] floral tones". Speyside: Speyside gets its name from the River Spey, which cuts through this region and provides water to many of the distilleries. Speyside has approximately 50 distilleries within its geographic boundaries and has officially been recognised as a region, distinct from the Highlands, since 2014.
Source Filmmaker (SFM) is a 3D animation application that was built from within the Source engine. Developed by Valve, the tool was originally used to create movies for Day of Defeat: Source and Team Fortress 2. It was also used to create some trailers for Source Engine games. SFM was released to the public in 2012.
Several degradation processes occur, some during cycling, some during storage, and some all the time: Degradation is strongly temperature-dependent: degradation at room temperature is minimal but increases for batteries stored or used in high temperature (usually > 35 °C) or low temperature (usually < 5 °C) environments. Also, battery life in room temperature is maximal. High charge levels also hasten capacity loss. Frequent charge to > 90% and discharge to < 10% may also hasten capacity loss. Keeping the li-ion battery status to about 60% to 80% can reduce the capacity loss. In a study, scientists provided 3D imaging and model analysis to reveal main causes, mechanics, and potential mitigations of the problematic degradation of the batteries over charge cycles. They found "[p]article cracking increases and contact loss between particles and carbon-binder domain are observed to correlate with the cell degradation" and indicates that "the reaction heterogeneity within the thick cathode caused by the unbalanced electron conduction is the main cause of the battery degradation over cycling". The most common degradation mechanisms include:
Sources: en.wikipedia.org
==== Metal exchange ==== Post-synthetic modification techniques can also be used to exchange an existing metal ion in a prefabricated MOF with a new metal ion by metal ion exchange. The complete metal metathesis from an integral part of the framework has been achieved without altering the framework or pore structure of the MOF. Similarly to post-synthetic ligand exchange, post-synthetic metal exchange is performed by washing prefabricated MOF crystals with solvent and then soaking the crystal in a solution of the new metal. Post-synthetic metal exchange allows for a simple route to the formation of MOFs with the same framework yet different metal ions.
By 1859, Cuba still did not have a Grand Lodge, and to accelerate this work, they contacted one of the most powerful figures of Freemasonry in the United States at the time, and today the most controversial figure in the history of North American Freemasonry, Albert Pike, requesting his guidance and assistance. Pike was at that time the Grand Commander of the Supreme Council of the Southern Jurisdiction of the United States for the Scottish Rite at Charleston, South Carolina.On March 26, 1859, Albert Pike gave his personal authority to the Cuban exile Andrés Cassard to create new offices, degrees, and bodies of the Scottish Rite in Cuba. However, later that year, Albert Pike and Albert Mackey also granted this authority to others in Cuba. Whether Cassard was aware of that is unclear. Four initiates from Fraternidad Lodge No. 387 joined three Cuban Freemasons living in Hudson, New York to formally petition the Grand Lodge of South Carolina to grant authority for a third Lodge. San Andres Lodge No. 93 was chartered in November 17, 1859. On November 27, 1859, the Grand Lodge of South Carolina granted a warrant to merge the three Cuban Lodges into the first Grand Lodge seen in Cuba in almost four decades; the Gran Logia de Colón (English: Grand Lodge of Columbus) at Santiago de Cuba. Under the authority Grand Lodge of Colon, the three Lodges were restructured as Fraternidad Lodge No.1, Prudencia Lodge No. 2, and San Andres Lodge No. 3. Francisco Griñán y Mozo served as the first Grand Master of the Grand Lodge of Colon.
== Journal of Wound Management == The Journal of Wound Management is the official journal of the European Wound Management Association (EWMA). Issues are published in January, May and October. EWMA Journal is CINAHL indexed and provides peer-reviewed original scientific articles, reviews, clinical information, and information about development in wound healing and management across Europe. The Journal also functions as a communication tool between EWMA, its members and the EWMA cooperating Organisations. The Journal is freely available online under terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) which means that anybody can copy, redistribute in any medium or format, adapt, remix, transform and make indicated changes with appropriate credit. It is prohibited to use the articles for commercial purposes. It is distributed to EWMA members and to members of national wound healing organisations in Europe, as well as to a wider audience via the internet. As a result, each issue of the EWMA Journal is distributed to 12-13,000 nurses, doctors and other health care professionals who have a special interest in wound care.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.